Recent advances in urological pharmacotherapy have highlighted the therapeutic potential of species-nonspecific but organ-specific polypeptides. Vesuten®, a bovine bladder polypeptide preparation, has shown promise in managing lower urinary tract dysfunction. This study investigates the efficacy and safety of intramuscular Vesuten® (5 mg lyophilisate) in patients with treatment-refractory primary bladder pain syndrome (BPS).

Twenty BPS patients (aged 40-71 years, mean 54.85±10.64) with cystoscopy-confirmed pathology under hydrodistention were enrolled in this therapeutic study. Participants received a 10-dose regimen of intramuscular Vesuten® (5 mg three times weekly). Treatment response was evaluated through voiding diaries and standardized instruments including ICSPI, VAS, PUF, IPSS, and PGI-I questionnaires.

The therapy demonstrated significant clinical improvements across multiple parameters. Mean bladder capacity increased from 82.4±25 mL to 98.2±24 mL (p<0.05), while daily voiding frequency decreased from 20.4±6.2 to 14.2±5.6 episodes (p<0.01). IPSS scores showed marked improvement (17.75±4.4 to 12.25±4.1, p<0.001), with parallel reductions in pain scores (VAS: 3.0±1.7 to 2.3±1.4). Seventy percent of participants reported meaningful symptomatic improvement on PGI-I assessment. No adverse events were documented during the study period.

The observed therapeutic effects of bovine bladder polypeptides in BPS patients may be attributed to their unique organ-specific regulatory properties. The statistically significant improvements in bladder capacity and voiding frequency suggest a potential trophic effect on the urothelium, possibly through modulation of tissue repair mechanisms. The reduction in pain scores, though modest, indicates a possible neuromodulatory action. These findings align with previous reports of polypeptide efficacy in overactive bladder syndrome, while extending their potential application to BPS management. The absence of adverse events further supports the safety profile of this biological therapy. However, the exact molecular mechanisms underlying these clinical effects warrant further investigation through proteomic and histological studies.

This clinical evaluation confirms the favorable safety profile of bovine bladder polypeptides (Vesuten®) in BPS management, with statistically significant improvements in both functional bladder parameters and patient-reported outcomes. The observed therapeutic effects support further investigation of organ-specific polypeptide therapy through randomized controlled trials to establish its role in contemporary BPS treatment algorithms.